#Taiwan #Taipei #oncology #Immunotherapy #HanchorBio

HanchorBio's Global Impact in Immunotherapy

HanchorBio, Inc. (TPEx: 7827), a prominent biotechnology company in the field of immunotherapy, has recently announced an ambitious lineup of scientific presentations scheduled for Q1 2026. This initiative reflects its commitment to advancing innovative treatment options for cancer patients worldwide. The presentations, which will take place at major international oncology conferences, are crucial to showcasing the clinical maturity and global scientific recognition of the company’s proprietary pipeline.

Highlights of HanchorBio's Upcoming Presentations

In early 2026, HanchorBio will present its significant research findings, featuring multiple abstracts that include four key oral presentations at top-tier conferences such as the American Association for Cancer Research Immuno-Oncology (AACR-IO) and the European Society for Medical Oncology Targeted Anticancer Therapies (ESMO-TAT). The focus will be on clinical data from ongoing studies for its lead drugs, HCB101 and HCB301, which have the potential to revolutionize cancer treatment through cutting-edge immunotherapy techniques.

HCB101 is designed as a highly engineered SIRPα–IgG4 Fc-fusion protein that maximizes phagocytosis while minimizing the associated hematologic toxicities often seen with traditional therapies. On the other hand, HCB301 targets multiple pathways including CD47/SIRPα and PD-1/PD-L1, showcasing a multi-faceted approach to overcoming the immunosuppressive tumor microenvironment (TME).

Conference Schedule and Insights

Following the successful presentation of data at the ASCO Gastrointestinal Cancers Symposium in San Francisco earlier in January, the company has scheduled several key appearances. The upcoming events include:

• - AACR Immuno-Oncology - Los Angeles, USA (Feb 18-21): 2 Posters
• - Asia-Pacific GI Cancer Congress - Okinawa, Japan (Mar 05-06): 1 Poster
• - ESMO Targeted Anticancer Therapies - Paris, France (Mar 16-18): 2 Orals, 1 Poster
• - ESMO Head and Neck Congress - Seville, Spain (Mar 19-21): 1 Oral
• - World Oncology Congress - Paris, France (Mar 23-25): 1 Oral

By presenting at these esteemed conferences, HanchorBio aims to demonstrate its capability to execute complex multi-center trials effectively, thereby reaffirming its role in the global oncology landscape. "The concentration of presentations at premier forums signifies the significant momentum of our clinical programs," stated Alvin Luk, PhD, MBA, who leads the company as President and Chief Medical Officer. He further emphasized that these presentations underscore the commitment to bringing next-generation therapies to patients on a global scale.

Innovations Behind HCB101 and HCB301

HCB101: The Next Generation SIRPα Fc-Fusion Protein

HCB101 represents an innovative approach to immunotherapy, developed using HanchorBio's proprietary FBDB™ platform. It selectively blocks the CD47–SIRPα innate immune checkpoint while aiming to preserve crucial antitumor activity mediated by macrophages. This design is pivotal in enhancing safety by minimizing adverse effects associated with traditional CD47-directed therapies. The unique structural design contributes to its ability to engage targets effectively without compromising patient well-being.

HCB301: Tri-Specific Checkpoint Immunotherapy

On the forefront of HanchorBio's therapeutic advancements is HCB301, a tri-specific candidate that embodies a comprehensive mechanism of action. By integrating multiple therapeutic pathways into one molecule, HCB301 aims to activate phagocytosis while restoring T-cell functionality and counteracting immune evasion. This novel approach positions HCB301 as a critical player in the pursuit of improved cancer therapies.

Looking Ahead

As HanchorBio gears up for its presentations at these leading congresses, the anticipation surrounding their innovative therapeutic candidates grows. With a robust pipeline and a dedicated team, HanchorBio is set to reshape the future of cancer care through groundbreaking immunotherapies. By showcasing its research at international platforms, HanchorBio not only elevates its clinical profile but also contributes significantly to the global fight against cancer. For more information about HanchorBio and its initiatives, visit HanchorBio's website.